AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01993719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day X 2 days intravenous (IV)
Study NCT01993719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
Study NCT01993719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
Study NCT01993719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV)
Study NCT01993719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
Study NCT04077008 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: unilateral drainage of Bilaterally Obstructed Kidneys
Description: drainage of obsructed kidneys by PCN or jj
Study NCT04077008 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral drainage of Bilaterally Obstructed Kidneys
Description: drainage of obsructed kidneys by PCN or jj
Study NCT03567239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using adaptive device.
Description: Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
Study NCT03810742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
Study NCT02767557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous infusion
Study NCT02767557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous infusion
Study NCT00472199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Study NCT00472199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00138645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MicroDiet
Description: MicroDiet
Study NCT02767557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion
Study NCT02767557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Intravenous infusion,
Study NCT02010385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Study NCT02010385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03864900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The medication adherence intervention
Description: The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
Study NCT02767557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Intravenous infusion,
Study NCT01194232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
Study NCT02352571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1118
Description: For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease.
Study NCT01963546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: different types of anesthesia
Study NCT01963546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
Study NCT03627546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Treatment strategy
Description: The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during 12 weeks of provided sofusbuvir/velpatasvir treatment.
Study NCT03627546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (facilitated referral)
Description: articipants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then followed separately. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
Study NCT04382547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
Description: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
Study NCT04382547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study NCT04382547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study NCT02824120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comedy
Description: patients will watch comedy film
Study NCT02824120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Documentary
Description: patients will watch a documentary film
Study NCT00521105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual visit
Description: Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
Study NCT04610190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with Gait Enhancing and Motivating System (GEMS-H) Robot
Description: Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
Study NCT05045391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aspergillus IgG detection
Description: Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.
Study NCT03507361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-BASED MUSIC
Description: Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.
Study NCT02590744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye patch
Description: cover the sick eye with eye patch preoperatively for 3 hours
Study NCT02590744 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: non-eye patch
Description: do not cover the sick eye with eye patch preoperatively
Study NCT01699009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant based diet
Study NCT01699009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: an unrestricted diet
Study NCT03514524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR imaging
Description: Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
Study NCT03573973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved product placement of fresh fruit and vegetables
Description: The intervention includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the placement (availability and position) of fresh fruit and vegetables.
Study NCT03573973 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
Study NCT02720718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratafix
Study NCT02720718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Study NCT02763046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457) 150 mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).
Study NCT02763046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457) 150 mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).
Study NCT02763046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Secukinumab (AIN457) 150 mg s.c.
Description: Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.
Study NCT00840749 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Radiotherapy
Description: Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
Study NCT00840749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
Study NCT00933907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 6 weeks
Study NCT01071642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
Study NCT01071642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE/ARB stopped 24 hours before procedure and start immediately after
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
Study NCT03079986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care irrespective of CL
Description: Removal of surgical drains despite persistent CL, without dietary restrictions or dietary treatment for CL.
Study NCT03079986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary treatment (MCT-diet)
Description: Dietary treatment with MCT-diet until resolution of CL.
Study NCT04038463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFP
Description: This intervention will take place on day 4 of the participants' menstrual cycle. This will correspond to the mid-point of the early follicular phase (EFP).
Study NCT04038463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LFP
Description: The intervention will take place on day 8 of the participants' menstrual cycle. This will correspond to the mid-point of the late follicular phase (LFP).
Study NCT04038463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELP
Description: The intervention will take place on day 18 of the participants' menstrual cycle. This will correspond to the mid-point of the early luteal phase (ELP).
Study NCT04038463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LLP
Description: The intervention will take place on day 25 of the participants' menstrual cycle. This will correspond to the mid-point of the late luteal phase (LLP).
Study NCT03926117 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ziltivekimab
Description: human IgG1k anti-human IL-6 monoclonal antibody
Study NCT03926117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: human IgG1k anti-human IL-6 monoclonal antibody
Study NCT06053346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pay For Performance (PFP)
Description: Wraparound mental health, psychosocial, and addiction treatment services provided by contractor under an schedule of rewards or penalties that was agreed to with Santa Clara County.
Study NCT06053346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Outpatient and inpatient mental health and psychosocial services delivered by Santa Clara County services and systems.
Study NCT02633293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
Study NCT02595918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy
Study NCT02595918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo nephrectomy
Study NCT02595918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03004274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Running sutures
Study NCT03004274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interrupted sutures
Study NCT02653963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctival Triamcinolone
Description: Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
Study NCT00794690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract for the group
Description: 40 mg of Cimicifuga racemosa extract daily dor 12 months
Study NCT03898791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: oral capsules
Study NCT00004919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00004919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00004919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given IV
Study NCT00004919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04237376 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Alafenamide 25 MG
Description: Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
Study NCT04237376 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Description: Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
Study NCT00483444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled telephone follow-up
Description: Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
Study NCT03977467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab at a flat dose of 1200 mg IV every 3 weeks
Study NCT03977467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Arm A Only)
Description: Standard of care chemotherapy is defined as a platinum-doublet therapy (or triplet if bevacizumab is used) of the Investigator's choice.
Study NCT03977467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: tiragolumab at a flat dose of 600 mg IV every 3 weeks
Study NCT00828217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
Study NCT00632268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001; Cisplatin; 5-FU; Leucovorin
Description: RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
Study NCT04948346 — intervention group
Intervention type: OTHER
Intervention: diagnosed with ALS
Description: diagnosed with ALS
Study NCT03655171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Video-based quantitative methods
Description: The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
Study NCT04588168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
Study NCT04588168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immediate Multiparametric MRI
Description: Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.
Study NCT04588168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy and Lymphadenectomy
Description: The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.
Study NCT04588168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: conventional Multiparametric MRI
Description: After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.
Study NCT04588168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Multiparametric MRI
Description: Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
Study NCT03760692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: Evaluation of clinical performance in terms of insertion, ventilation and complications
Study NCT02717624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib in combination with BR
Study NCT03760692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuroGain
Description: Evaluation of clinical performance in terms of insertion, ventilation and complications
Study NCT01805063 — intervention group
Intervention type: PROCEDURE
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
Study NCT01805063 — intervention group
Intervention type: PROCEDURE
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study NCT03743051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin Hydrochloride
Description: 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)